Home Interviews Biosergen attacks invisible threat of fungal infections

Biosergen attacks invisible threat of fungal infections

BioSergen CEO Tine Kold Olesen and CFO Niels Laursen in BioStock Studio

Biosergen attacks invisible threat of fungal infections

8 March, 2024

How big is the threat of fungal infections and the strains that develop drug resistance? Swedish biotech company Biosergen develops antimyotic drugs that they hope will become market leading. Newly appointed CEO Tine Kold Olesen visited the BioStock Studio to discuss the invisible threat of fungi and the company’s partnership for the Indian market. In addition, CFO Niels Laursen talked about the ongoing rights issue of SEK 40.5 million and what it will finance.

Watch the interview with Biosergen’s CEO Tine Kold Olesen and CFO Niels Laursen below.

YouTube video

This material has been created for marketing purposes and is not and shall not be deemed to constitute a prospectus under applicable laws and regulations. The complete terms and conditions of the rights issue and more information about the company have been presented in a prospectus that was published on biosergen.net March 5 2024.

Prenumerera på BioStocks nyhetsbrev